Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521549 | 0.88 | EGLN1 (0.53) | MERTKEGLN1GLATRPV1ADORA2A | |
| SCHEMBL3405965 | 0.85 | EGLN1 (0.52) | MERTKEGLN1NAMPTFLT3TYRO3 | |
| SCHEMBL3411065 | 0.84 | TACR1 (0.48) | MERTKEGLN1 | |
| SCHEMBL3428275 | 0.84 | EGLN1 (0.67) | MERTKEGLN1GLATRPV1 | |
| SCHEMBL3404652 | 0.83 | EGLN1 (0.56) | MERTKEGLN1GLA | |
| SCHEMBL4527932 | 0.83 | EGLN1 (0.47) | MERTKEGLN1FLT3TYRO3GAS6 | |
| SCHEMBL3407244 | 0.83 | EGLN1 (0.51) | MERTKEGLN1NAMPTFLT3TYRO3 | |
| SCHEMBL3430237 | 0.83 | EGLN1 (0.51) | MERTKEGLN1FLT3TYRO3GAS6 | |
| SCHEMBL3409246 | 0.83 | EGLN1 (0.64) | MERTKEGLN1 | |
| SCHEMBL16005776 | 0.83 | EGLN1 (0.52) | MERTKEGLN1FLT3TYRO3GAS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | claimed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | claimed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | claimed |
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | HIF1AN, EGLN2, EGLN3 | MERTK 1997/4885EGLN1 5/4885NAMPT 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.